2 completed, 2 unknown, 1 active not recruiting, 1 recruiting. 7 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 2, Unknown 2, Active not recruiting 1, Recruiting 1, Terminated 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow SEphB4-HSA: new trials by email Literature Review of SEphB4-HSA trials Research Report on SEphB4-HSA
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors SEphB4-HSA, Pembrolizumab, Gemcitabine - Muscle-Invasive Bladder Carcinoma, Metastatic Urothelial Carcinoma | Phase 2 / Phase 3 | Recruiting | Vasgene Therapeutics, Inc | 700 | 2025-03-15 | 2025-04-03 |
| A Study of sEphB4-HSA in Kaposi Sarcoma sEphB4-HSA - Kaposi Sarcoma | Phase 2 | Unknown | Vasgene Therapeutics, Inc | 65 | 2020-09-17 | 2024-05-02 |
| sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Recombinant EphB4-HSA Fusion Protein - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 2 | Unknown | Northwestern University | 14 | 2019-09-20 | 2022-04-27 |
| sEphB4-HSA in Treating Patients With Kaposi Sarcoma Laboratory Biomarker Analysis, Pharmacological Study, Quality-of-Life Assessment - Skin Kaposi Sarcoma | Phase 2 | Completed | AIDS Malignancy Consortium | 23 | 2018-02-13 | 2026-06-01 |
| Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent Azacitidine, Decitabine, Laboratory Biomarker Analysis - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia | Phase 2 | Terminated | University of Southern California | 7 | 2017-04-20 | 2026-06-08 |
| Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475 Laboratory Biomarker Analysis, Pembrolizumab, Recombinant EphB4-HSA Fusion Protein - ALK Gene Mutation, BRAF Gene Mutation | Phase 2 | Completed | University of Southern California | 42 | 2017-03-10 | 2025-10-22 |
| Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors Computed Tomography, Laboratory Biomarker Analysis, Pembrolizumab - Stage IV Bladder Urothelial Carcinoma, Prostate Cancer | Phase 2 | Active not recruiting | University of Southern California | 70 | 2016-11-21 | 2026-06-09 |
Carcinoma, Transitional Cell (2) · Prostatic Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (1) · Disease Progression (1) · Leukemia, Myeloid, Acute (1) · Leukemia, Myelomonocytic, Chronic (1) · Sarcoma, Kaposi (1) · Squamous Cell Carcinoma of Head and Neck (1)
University of Southern California (3) · Vasgene Therapeutics, Inc (2) · AIDS Malignancy Consortium (1) · Northwestern University (1)
United States (7)
Sarmad Sadeghi, MD (2) · Carl Millner, M.D. (1) · Casey O'Connell, MD (1) · Ida Wong-Sefidan (1) · Jorge Nieva, MD (1) · Maha H Hussain, M.D. (1)
P30CA014089 (3), P30CA060553 (1), U01CA121947 (1)